This week, these ten stocks, all currently earning A’s (“strong buy”) on , have the best year-to-date performance. Since the beginning of the year, the Nasdaq 15.3%, the Dow is up 7.7%, and the S&P has increased 13.3%.
Shares of US Airways (NYSE:) have risen 151% since January 1. US Airways Group provides air transportation for passengers and cargo. The stock currently has a trailing PE Ratio of 4.00. .
Since January 1, CVR Energy (NYSE:) has climbed 151.3%. CVR Energy engages in refining and marketing transportation fuels in the United States. .
Since January 1, the price of Conn’s Inc. (NASDAQ:) has grown 156.8%. Conn’s is a specialty retailer of home appliances and consumer electronics. .
Shares of PulteGroup (NYSE:) have leapt 171.4% since January 1. PulteGroup sells and constructs homes, and purchases, develops, and sells residential land and develops active adult communities. .
Since January 1, Nam Tai Electronics (NYSE:) has shot up 173.6%. Nam Tai Electronics is an electronics design and manufacturing services provider to original equipment manufacturers. .
The price of Lumber Liquidators
(NYSE:) is up 176.8% since the first of the year. Lumber Liquidators retails hardwood flooring in the United States. .
Since the first of the year, the price of Santarus (NASDAQ:) has swelled 215.2%. Santarus, Inc. was incorporated in California in December 1996 and reincorporated in Delaware in July 2002. It is a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists and other targeted physicians. .
Since the first of the year, shares of 3D Systems (NYSE:) have soared 218.1%. 3D Systems engages in the design, development, manufacture, marketing, and servicing of 3D printers and related products, print materials, and services. .
Since January 1, Regeneron Pharmaceuticals (NASDAQ:) has jumped 224.4%. Regeneron Pharmaceuticals researches, develops and commercializes therapeutics to treat human disorders and conditions. .
Pharmacyclics (NASDAQ:) has risen 312.8% since the first of the year. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. .
Louis Navellier’s proprietary stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool .
